Tag: ordinary shares

Statement regarding the proposed issue of a prospectus

Nanjing, China, June 18, 2026 (GLOBE NEWSWIRE) -- Scage Future (Nasdaq: SCAG) (“Scage” or the “Company”), a zero-emission solution provider of new energy heavy-duty commercial vehicles and e-fuel solutions, today announced that the Company received a notification letter (the “Notification Letter”) from the Listings Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on June 11, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement as set forth under Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq. This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure upon the receipt of a deficiency notification.

Press release
Paris, 18 June 2026

REYKJAVIK, ICELAND (June 18, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing on June 17, 2026 of its previously announced underwritten public offering (the “Offering”) of 26,066,667 of its ordinary shares at an offering price of $3.75 per share, which includes 3,400,000 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the Offering. All ordinary shares sold in the Offering were offered by Alvotech. Before deducting the underwriting discounts and commissions and offering expenses, the aggregate gross proceeds to the Company were approximately $98 million.

BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares (“ADSs”), each representing two ordinary shares of the Company, at a public offering price of $29.35 per ADS. In addition, Legend Biotech has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 ADSs at the public offering price, less underwriting discounts and commissions. All of the ADSs are being offered by Legend Biotech. The gross proceeds to Legend Biotech from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Legend Biotech, are expected to be approximately $226 million, excluding any proceeds from the exercise of the underwriters’ option to purchase additional ADSs. The offering is expected to close on June 23, 2026, subject to customary closing conditions.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Regencell (RGC) To Contact Him Directly To Discuss Their Options

Miami, FL, June 17, 2026 (GLOBE NEWSWIRE) -- Collective Acquisition Corp. II (Nasdaq: CAIIU) (the “Company”) announced today that, commencing June 22, 2026, holders of the units issued in the Company’s initial public offering (the “Units”), each consisting of one Class A ordinary share of the Company (the “Class A Ordinary Shares”) and one-half of one redeemable warrant of the Company (each whole warrant, a “Warrant”), with each whole Warrant entitling the holder thereof to purchase one Class A Ordinary Share at an exercise price of $11.50 per share, may elect to separately trade the Class A Ordinary Shares and Warrants included in the Units. No fractional Warrants will be issued upon separation of the Units and only whole Warrants will trade. The Class A Ordinary Shares and Warrants will trade on the Nasdaq Global Market under the symbols “CAII” and “CAIIW,” respectively. Units not separated will continue to trade on the Nasdaq Global Market under the symbol “CAIIU.”

Guangdong, China, June 16, 2026 (GLOBE NEWSWIRE) -- Wing Yip Food Holdings Group Limited (the “Company” or “Wing Yip”) (Nasdaq: WYHG), a meat product processing company in mainland China, today announced that it received a formal notification from the Nasdaq Stock Market LLC (“Nasdaq”) on June 16, 2026 that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company’s American Depositary Shares (“ADSs”) to maintain a minimum bid price of US$1.00 per share. As previously disclosed, on December 22, 2025, the Company received a notification from Nasdaq indicating that the closing bid price of the Company’s ADSs had been below US$1.00 per share for the prior 30 consecutive business days and that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2).

SINGAPORE, June 16, 2026 (GLOBE NEWSWIRE) -- Trident Digital Tech Holdings Ltd (“Trident” or the “Company,” NASDAQ: TDTH), a leading catalyst for digital transformation in technology optimization services and Web 3.0 activation based in Singapore, today announced its plan to terminate the amended and restated Deposit Agreement dated September 11, 2024, as amended, by and among the Company, Citibank, N.A. (the “Depositary”), and the holders of American depositary shares (the “ADSs”) from time to time (the “Deposit Agreement”), effective July 16, 2026 (the “Termination”).